Remission Rates, Time to Remission, and Related Factors in Adolescents with Major Depressive Disorder

Zehra Topal; Yusuf Öztürk; Nuran Demir; Oznur Adıgüzel; Mehmet Karadağ; Ali Evren Tufan

doi:10.5152/eurjther.2021.20081

Authors

Zehra Topal Department of Child and Adolescent Psychiatry, Gaziantep University School of Medicine, Sahinbey Research and Practice Hospital, Gaziantep, Turkey https://orcid.org/0000-0001-8397-5636
Yusuf Öztürk Department of Child and Adolescent Psychiatry, Abant _ Izzet Baysal University Faculty of Medicine, Bolu, Turkey https://orcid.org/0000-0002-3412-9879
Nuran Demir Department of Child and Adolescent Psychiatry, Yıldırım Bayezit University, Ankara, Turkey https://orcid.org/0000-0002-4322-7251
Oznur Adıgüzel Department of Child and Adolescent Psychiatry, Ordu University Training & Research Hospital, Ordu, Turkey https://orcid.org/0000-0001-8196-6664
Mehmet Karadağ Department of Child and Adolescent Psychiatry, Gaziantep University School of Medicine, Sahinbey Research and Practice Hospital, Gaziantep, Turkey https://orcid.org/0000-0002-4130-0494
Ali Evren Tufan Department of Child and Adolescent Psychiatry, Acıbadem Mehmet Ali Aydınlar University, _ Istanbul, Turkey https://orcid.org/0000-0001-5207-6240

DOI:

https://doi.org/10.5152/eurjther.2021.20081

Keywords:

Adolescent depression, treatment outcomes, remission

Abstract

Objective: Major depressive disorder (MDD) is a common disorder in children and adolescents that can cause serious morbidity and mortality. Although response rates to treatment are high, less than half of the adolescents with MDD achieve remission. The present study aims to evaluate remission rates, time to remission, and the predictors of remission in adolescents with MDD. Methods: This study included 34 adolescents with MDD who were followed-up for a minimum period of 120 days. The adolescents were assessed with the Clinic Global Impression Scale, Beck Depression Inventory, Young Mania Rating Scale, Child Mania Rating Scale, and Screen for Child Anxiety-Related Emotional Disorders at the baseline and at weeks 4, 8, and 12. Results: 67.6% of the adolescents had at least one comorbid diagnosis. The remission rate at week 12 was 73.5%. The mean time to remission was 72.0 days. The female adolescents achieved a significantly higher remission rate than the males. Conclusion: The majority of adolescents achieved remission following acute treatment, and that the time to remission for the female adolescents was shorter compared with the males. Remission time does seem neither to be related to the number of medications prescribed nor to the number of comorbid diagnoses

Metrics

Metrics Loading ...

References

Birmaher B, Brent D, Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with

depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503-1526.

Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J. Childhood and adolescent depression: A review of the past 10 years.

Part II. J Am Acad Child Adolesc Psychiatry. 1996;35(12):1575-1583.

Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry. 2003;64(Suppl. 18):3-7.

Topal Z, Tufan AE. Clinical presentation, diagnosis and treatment of dysthimic disorder and recurrent depressive disorder in children

and adolescents. Turkiye Klinikleri J Child Psychiatr Spec Top. 2016;2(1):79-84.

Scott K, Lewis CC, Marti CN. Trajectories of symptom change in the treatment for adolescents with depression study. J Am Acad Child

Adolesc Psychiatry. 2019;58(3):319-328.

Israel JA. Remission in depression: Definition and initial treatment approaches. J Psychopharmacol. 2006;20(3 Suppl.):5-10.

Han D, Wang EC. Remission from depression: A review of venlafaxine clinical and economic evidence. Pharmacoeconomics.

;23(6):567-581.

Keller MB. Remission versus response: The new gold standard of antidepressant care. J Clin Psychiatry. 2004;65(Suppl. 4):53-59.

Guelfi JD. Measuring remission in depression. Medicographia. 2009;31(2):192-197.

Hisli N. Beck depresyon envanterinin universite ogrencileri icin gecerliligi, guvenilirligi (A reliability and validity study of beck

depression inventory in a university student sample). J Psychol. 1989;7:3-13.

Birmaher B, Khetarpal S, Brent D, et al. The screen for child anxiety related emotional disorders (SCARED): Scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry. 1997;36(4):545-553.

Çakmakcı Ç. Çocuklarda anksiyete bozukluklarını tarama o¨ lc¸eg˘ I gec¸erlik ve gu¨ venirlik c¸alısması. Yayınlanmamıs uzmanlık tezi,

KocaeliU¨ niversitesi Tıp Faku¨ ltesi, Kocaeli, 2004.

Karadag˘ F, Oral ET, Aran Yalc¸ın F, Erten E. Young mani derecelendirme o¨ lc¸eg˘ inin Tu¨ rkiye’de gec¸erlik ve gu¨ venilirlig˘ i. Tu¨rk Psikiyatri

Dergisi. 2001;13(2):107-114.

Pavuluri MN, Henry DB, Devineni B, Carbray JA, Birmaher B. Child mania rating scale: Development, reliability, and validity.

J Am Acad Child Adolesc Psychiatry. 2006;45(5):550-560.

Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, 1976.

Yorbik O, Birmaher B, Axelson D, Williamson DE, Ryan ND. Clinical characteristics of depressive symptoms in children and adolescents with major depressive disorder. J Clin Psychiatry. 2004;65(12):1654-1659.

Fergusson DM, Horwood LJ, Ridder EM, Beautrais AL. Subthreshold depression in adolescence and mental health outcomes in adulthood. Arch Gen Psychiatry. 2005;62(1):66-72.

Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit E. A comparison of cognitive-behavioral therapy, sertraline, and their

combination for adolescent depression. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1151-1161.

Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiat.

;46(7):735-754.

Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the treatment of adolescents

with depression study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45(12):1404-1411.

Kennard BD, Silva SG, Tonev S, et al. Remission and recovery in the treatment for adolescents with depression study (TADS): Acute

and long-term outcomes. J Am Acad Child Adolesc Psychiatry. 2009;48(2):186-195.

Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54(11):1031-1037.

Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, et al. Fluoxetine for acute treatment of depression in children and adolescents: A

placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1205-1215.

Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the

treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161(6):1079-1083.

Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP task force on response and remission in major depressive disorder.

Neuropsychopharmacol. 2006;31(9):1841-1853.

Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the treatment for adolescents with depression

study (TADS). J Am Acad Child Adolesc Psychiatry. 2006;45(12):1427-1439.

Lewis CC, Simons AD, Silva SG, et al. The role of readiness to change in response to treatment of adolescent depression. J Consult

Clin Psychol. 2009;77(3):422-428.

Lewis CC, Simons AD, Nguyen LJ, et al. Impact of childhood trauma on treatment outcome in the treatment for adolescents

with depression study (TADS). J Am Acad Child Adolesc Psychiatry. 2010;49(2):132-140

Remission Rates, Time to Remission, and Related Factors in Adolescents with Major Depressive Disorder

Authors

DOI:

Keywords:

Abstract

Metrics

References

Downloads

Published

How to Cite

Issue

Section

License

Make a Submission

Journal Metrics

Become a Reviewer

Indexing & Abstracting

Journal History

Information

Keywords